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Objective:  To investigate  the risk  of intussusception  after  monovalent  rotavirus  vaccine  (RV1)  given  to
infants  aged  2  and  3 months  in England.
Methods:  Hospital  Episode  Statistics  (HES)  were  used  to identify  infants  aged  48–183  days  admitted
between  11/03/2013  and  31/10/2014  with  intussusception.  Diagnosis  was  conﬁrmed  from  medical
records  and  HES  procedure  codes.  Vaccination  status  was  obtained  from  general  practitioners.  The  risk
of admission  within  1–7 and  8–21  days  of  vaccination  was analysed  using  the  self-controlled  case-series
(SCCS)  method  with  age  effect  adjustment  by  including  historical  data  before  RVI introduction  in July
2013.
Results:  A  total of  119  cases  were  identiﬁed  during  the  study  period  and  intussusception  conﬁrmed  in 95
of  whom  39  were  vaccinated  1–21  days  before  onset.  An  increased  relative  incidence  (RI) in this  period
was  found,  4.53  (95%  conﬁdence  interval  2.34–8.58)  and  2.60  (1.43–4.81)  respectively  after  the  1st  and
2nd  doses  with  an attributable  risk  of  1.91 and  1.49 per  100,000  doses  respectively.  The  peak  risk  was
1–7  days  after  the  ﬁrst dose,  RI  13.81  (6.44–28.32),  with  an  estimated  93%  of the  15 cases  being  vaccine-
attributable.  Mean  interval  between  onset  and  admission,  and  clinical  features  were  similar  between
vaccine-associated  and  background  cases.  Despite  intussusception  being  a contraindication  to rotavirus
vaccination,  10  infants  received  a further  dose;  none  had a  recurrence.  The  RIs in a meta-analysis  combing
our  results  with  Australia,  Mexico,  Brazil  and  Singapore  using  RV1,  a 2, 4 month  schedule  and  SCCS  gave
pooled  RI  estimates  of 2.35  (1.45–3.8)  and  1.77  (1.29–2.43)  in  the 21  day  period  after  the  1st  and  2nd
doses,  respectively.  The  earlier  age  at  the  2nd  dose  in  England  did  not  affect the  risk.
Conclusion:  We  estimate  that  the  RVI  programme  causes  around  21  intussusception  admissions  annually
in  England  but,  since  it prevents  around  25,000  gastro-intestinal  infection  admissions,  its  beneﬁt/risk
proﬁle  remains  strongly  positive.
Crown  Copyright  © 2016  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).. Introduction
Rotavirus infects nearly every child by ﬁve years of age and
s the leading cause of gastroenteritis worldwide [1]. In healthy
nfants in developed countries the infection results in a mild self-
imiting illness with low mortality though it has a high healthcare
urden and causes parental anxiety [2]. It is estimated that in
ngland and Wales in the absence of vaccination rotavirus infection
s responsible for around 45% of hospitalisations, 20% of accident
nd emergency attendances and 25% of primary care consulta-
ions for acute gastroenteritis in children under ﬁve years of age,
∗ Corresponding author. Tel.: +44 2083277485.
E-mail address: Julia.Stowe@phe.gov.uk (J. Stowe).
ttp://dx.doi.org/10.1016/j.vaccine.2016.04.050
264-410X/Crown Copyright © 2016 Published by Elsevier Ltd. This is an open access ar
d/4.0/).corresponding to annual incidences per 1000 of 4.5, 9.3 and 28–44
consultations respectively [3].
The ﬁrst rotavirus vaccine, Rotashield®, was shown to have an
attributable risk of intussusception of between 10.5 and 21.4 per
100,000 infants vaccinated [4] and was withdrawn from the mar-
ket. Subsequently two new rotavirus vaccines were licensed, one
containing a monovalent attenuated human rotavirus strain (RV1)
and the other a pentavalent human-bovine reassortant vaccine.
Although a risk of this magnitude was  not seen with these new
rotavirus vaccines in randomised controlled trials, they lacked the
power to rule out a small risk [5,6]. In post-licensure studies, an
increased risk of intussusception after the ﬁrst dose of these vac-
cines has been reported in the 1–7 day post-vaccination period
with an attributable risk after the ﬁrst dose of between 1.1 to 4.3
per 100,000 [7–12]. The risk following the second dose appears to
ticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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e smaller, with most studies not ﬁnding a signiﬁcantly increased
isk.
In the United Kingdom (UK) the rotavirus vaccine was ﬁrst added
o the routine vaccination programme in July 2013 using the RV1
accine, Rotarix® (GlaxoSmithKline). It is given as a 2 dose schedule
t 2 and 3 months with the second dose to be given by 24 weeks of
ge to avoid coinciding with the peak in the background incidence
f intussusception around this time [13]. Rotarix® is contraindi-
ated for infants who have had a prior intussusception episode
r an uncorrected congenital malformation of the gastrointestinal
ract that would predispose to intussusception. Since its introduc-
ion in the UK, the uptake of rotavirus vaccine has been high, with
 77% decline in laboratory-conﬁrmed rotavirus infections and a
6% decline in all-cause acute gastroenteritis-associated hospitali-
ations compared with the pre-vaccination era [14].
In this study, we investigate whether there is an increased risk
f intussusception following either the ﬁrst or second dose of RV1
accine in infants in England. We  also examine the timeliness of
resentation to hospital which is essential in preventing complica-
ions from this rare event.
. Methods
The Hospital Episode Statistics (HES) [15] database was used
o identify cases of intussusception in infants eligible to receive at
east one dose of rotavirus vaccine from the start of the national
rogramme until 31/10/2014. The HES database contains details
f all admissions to National Health Service hospitals in England.
nfants aged 42–183 days old at the start of their admission with
n ICD-10 code for intussusception in the primary diagnosis ﬁeld
nd born from 11/03/2013 were selected as the vaccine was  made
vailable to any babies born up to 15 weeks prior to vaccine intro-
uction on 1st July 2013. Ofﬁce of Population Censuses and Surveys
OPCS) Classiﬁcation of Interventions and Procedures version 4
odes attached to each admission were also extracted to investigate
ny procedures or operations during that admission. An admission
or intussusception within 3 days of a previous one was  treated as
he same admission.
As rotavirus vaccine is delivered in primary care, infants’ gen-
ral practitioners were contacted to ascertain whether the vaccine
as given and, if so, the date(s). Each case was categorised accord-
ng to the Brighton Criteria for intussusception which contain 3
evels of diagnostic certainty [16]; level 1 is the highest level of
ertainty requiring conﬁrmation by surgical or radiological reduc-
ion of the intussusception; level 2 is assigned by the evidence on
 number of diagnostic features including intestinal obstruction,
ntestinal invagination and blood per rectum. Level 3 cases, which
omprise those where the diagnostic evidence was less robust,
ere excluded from the analysis, together with cases for whom
linical information was lacking.
Diagnosis level was assigned without knowledge of vaccination
tatus based on three sources of information; OPCS codes that indi-
ated whether a surgical or radiological procedure was undertaken
o reduce the intussusception, any additional information from the
P on treatment and symptoms, validated by a copy of the hospi-
al discharge summary where available, and if no information was
vailable from the HES database or GP, the paediatrician involved in
he patient’s care was contacted. Information from the GP and the
ischarge summaries was used to ascertain the date of ﬁrst symp-
oms. For the analysis a single event date was determined which
as the date of onset identiﬁed by the GP or in the hospital let-
ers, or where this information was lacking, the date of hospital
dmission. Where the onset of symptoms was more than 3 days
rior to admission this was only taken as the episode onset if on (2016) 3684–3689 3685
blinded review the events on this date were clearly part of the
intussusception event.
The self-controlled case-series (SCCS) method was  used to test
the hypothesis of an increased risk of intussusception in three risk
periods of 1–7, 8–21 and overall 1–21 days after rotavirus vacci-
nation, where day 0 is the day of vaccination. The SCCS method
[17] automatically controls for time-invariant confounding and
has been used in previous studies investigating vaccine and intus-
susception [7,8,10,18]. We  used the adaptation of the method
developed by Farrington et al. [19] because the standard SCCS
approach could not be used as intussusception is a contraindica-
tion to vaccination, thus violating the assumption that vaccination
is not dependent on the occurrence of the event.
Age adjustment was  by 2 weekly intervals, but age had a degree
of collinearity with vaccine risk periods due to the lack of control
person time around the time of vaccination because the doses were
only given a month apart and the risk interval was  3 weeks. To
address this, a pre-speciﬁed additional analysis was  planned where
ﬁve years of historical HES intussusception data from the period
prior to vaccine introduction was  included to enable better esti-
mates of age effects. For these cases, hospital admission date was
used as the index date.
Sample size calculations based on HES incidence data by age
indicated that the expected number of cases from a year of follow-
up post-vaccine introduction in the 7 day period after doses one
and two  was  1.6 and 4.0 respectively. This would enable detection
of risks (80% power, 5% signiﬁcance) of about 5–6 fold after dose 1
and 3–4 fold after dose 2.
The attributable risk was  calculated from the relative incidence
(RI) estimates. First the attributable fraction (AF) was calculated
as (RI-1)/RI for each period after each dose. This was then applied
to the cases observed to get an attributable number of cases, and
ﬁnally this was divided by the estimated number of vaccine doses
given to the population from which the cases arose.
To compare cases that were likely to be vaccine-associated with
those that were not the features of the cases, including treatment,
duration of admission and length of time from symptoms to admis-
sion in the 1–7 day risk interval after the ﬁrst dose were compared
to those outside the 1–21 day risk period after either dose. Logis-
tic regression was  used to adjust for age when comparing these
groups.
A random effects meta-analysis was performed, combining our
results with those from four other countries using RV1 and repor-
ting RI estimates by the SCCS method [7,8,10,11]. Estimates for
the 8–21 and 1–21 day post-vaccination risk periods were not
reported for every country; however, these could be derived from
the reported estimates in other risk periods. Pooled estimates were
then obtained for the 1–7, 8–21 and 1–21 day post-vaccination
periods using the point estimates and 95% conﬁdence intervals (CIs)
from each country. Analysis was  carried out using Stata version 13
(StataCorp, College Station, TX).
3. Results
A total of 590 admissions in the period 1/07/08 to 31/10/2014
were identiﬁed from HES, with age at admission from 42 to 183 days
and a K561 ICD-10 code for intussusception in the primary diagno-
sis ﬁeld. There were 471 episodes in the 5 years prior to vaccine
introduction with a date of birth before 11/03/2013 (age distribu-
tion shown in Fig. 1), and 119 with a date of birth after 10/03/2013
and, therefore, eligible for vaccination. Of the 119 episodes in the
vaccine-eligible period, 90 were conﬁrmed as Brighton level 1 after
review and ﬁve as Brighton level 2. Of the remaining 29, one episode
was assigned level 3, eight did not ﬁt the criteria for intussuscep-
tion and, for the remaining 15, the relevant information could not
3686 J. Stowe et al. / Vaccine 34 (2016) 3684–3689
Table 1
Description of the 95 Brighton level 1 and 2 intussusception cases included in the risk analysis, that are in the risk period 1–21 days after dose 1 or 2 of rotavirus vaccine.
Variable Level Count of cases in risk period Count of cases outside the risk period Total count (%)
Sex Male 29 37 66 (69%)
Female  10 19 29 (31%)
Radiological reduction No 17 26 43 (45%)
Yes  22 30 52 (55%)
Surgery No  23 34 57 (60%)
Yes  16 22 38 (40%)
Brighton 1  38 52 90 (95%)
2  1 4 5 (5%)
Vaccine doses 0 0 13 13 (14%)
1  12 7 19a (20%)
2  27 36 63b (66%)
Age 6w–9w/6d 10 4 14 (15%)
10w–13w/6d 11 8 19 (20%)
14w–17w/6d 15 12 27 (28%)
18w–21w/6d 2 16 18 (19%)
22w–26w/1d 1 16 17 (18%)
a 1 individual had onset before vaccination.
b 12 individuals had onset before vaccination (2 before ﬁrst dose, 10 between doses).
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8Fig. 1. Age distribution of the historic cases.
e traced. Copies of medical discharge summaries and letters were
vailable for 72 of the 95 level 1 and 2 cases (76%). Of the 95 cases,
6 (69%) were in males with an age range of 6–26 weeks (Table 1).
Overall there were 20 intussusception events 1–21 days after
ose one and 19 events in the same period after dose two (Table 2
nd Fig. 2). After the ﬁrst dose, 15 of the 20 cases occurred in the
–7 day period, with the interval between vaccination and onset of
ymptoms ranging from 4 to 6 days. After the second dose, there
ere 5 cases in the 1–7 day post-vaccination risk period and 14 in
he 8–21 day risk period. A signiﬁcantly increased risk was  seen in
he overall 1–21 day period post-vaccination for both the ﬁrst and
econd dose of rotavirus vaccine (RI, 4.53; 95% CI, 2.34–8.58, and
I, 2.60; 95% CI, 1.43–4.81, respectively) (Table 2). When this post-
accination risk period was spilt into 1–7 days and 8–21 days, the
I in the period 1–7 days after the ﬁrst dose and 8–21 days after
he second dose remained signiﬁcantly elevated (Table 2). When
he cases born before 11/03/2013 were included, the age effects
ere better speciﬁed which improved precision of the vaccine risks.
he model incorporating the historic data also happened to give a
ower background incidence in the younger age groups than the
odel without these data which led to higher relative incidence
stimates for the vaccine risk periods (Table 2).
Using the model with the historical age data, the attributable
ractions for days 1–7 and 8–21 after doses one and two were
3%, 37%, 55% and 64%, respectively, and the estimated number of
accine-attributable cases 13.91, 1.86, 2.73 and 8.94 respectively.
ased on dose one and two national vaccine coverage of 93.3% and
8.3% [20] and an England population estimate for infants underFig. 2. Distribution of intussusception events 4 weeks before to 10 weeks after
monovalent rotavirus vaccine doses 1 and 2.
1 year of age of 664,517 [21] and 1 year 4 months follow-up, the
number of ﬁrst and second doses given were around 826,659 and
782,358, respectively. The attributable risk in the 1–21 day period
after dose one was, therefore, 15.77/826,659 (1.91 per 100,000
doses) and 11.67/782,358 (1.49 per 100,000 doses) after dose two.
For the 1–7 day period after dose one only, the attributable risk is
1.68 per 100,000 doses.
Fifty-two (55%) of the 95 cases had their intussusception
reduced radiologically, 38 (40%) underwent surgery and 5 had no
intervention. In the 15 infants with intussusception in the 1–7 days
after the ﬁrst dose, 8 (53%) had radiological reduction and 7 (47%)
J. Stowe et al. / Vaccine 34 (2016) 3684–3689 3687
Table  2
Relative incidence of intussusception in risk periods after ﬁrst and second monovalent rotavirus vaccine doses.
Historical cases for age effect Dose Risk period (days) Cases in risk period RI (95% CIa)
Yes 1 1–7 15 13.81 (6.44–28.32)
8–21 5 1.59 (0.34–3.75)
1–21 20 4.53 (2.34–8.58)
2  1–7 5 2.20 (0.50–5.02)
8–21 14 2.77 (1.36–5.32)
1–21 19 2.60 (1.43–4.81)
No  1 1–7 15 8.50 (3.27–28.75)
8–21 5 1.18 (0.28–3.99)
1–21 20 3.13 (1.34–7.57)
2  1–7 5 1.74 (0.37–5.16)
8–21 14 2.74 (1.22–5.89)
1–21 19 2.41 (1.15–5.59)
a Percentile bootstrap (n = 1000) 95% conﬁdence intervals.
Table 3
Features of the intussusception admissions in infants in the 1–7 day post ﬁrst dose risk period compared to those outside vaccine risk periods.
Feature 1–7 days post ﬁrst dose n/N (%) Out of risk period-baselineb n/N (%) Odds ratio (95%CI)a
Treatment
Radiological 8/15 (53.3%) 30/56 (53.6%) 0.96 (0.24–3.91)
Surgical 7/15 (46.7%) 22/56 (39.3%) 1.58 (0.38–6.59)
Days  from onset to admission
Same day 5/15 (33.3%) 29/56 (51.8%) 1.04 (0.24–4.60)
Mean  (range) in days 0.71 (0–4) 0.77 (0–4)
Duration of admission
0–1 days 9/15 (60.0%) 32/56 (57.1%) 0.44 (0.11–1.85)
Mean  (range) in days 0.33 (0–8) 0.50 (0–12)
Gender
Male 10/15 (66.7%) 37/56 (66.1%) 0.54 (0.11–2.58)
a Odds ratio adjusted for in age in days.
b Not within 1–21 days of dose 1 or 2.
Table 4
Meta-analysis of results from four countries using monovalent rotavirus vaccine: relative incidence and 95% conﬁdence intervals.
Country Period post dose 1 Period post dose 2
1–7 days 8–21 days 1–21 days 1–7 days 8–21 days 1–21 days
Australia 6.76 (2.40–19.01) 3.45 (1.33–8.94) 4.55 (2.21–9.38)a 2.84 (1.10–7.34) 2.11 (0.97–4.62) 2.35 (1.28–4.33)a
Mexico 5.30 (3.00–9.30) 0.99 (0.52–1.91)b 2.43 (1.51–3.90)a 1.80 (0.90–3.80) 2.20 (1.40–3.45)b 2.07 (1.41–3.04)a
Singapore 8.36 (2.42–28.96) 0.10 (0.01–10.0)c 2.85 (1.13–7.19)a 3.09 (0.41–12.37) 1.54 (0.20–11.69) 2.06 (0.47–8.94)a
Brazil 1.10 (0.30–3.30) 0.51 (0.20–1.33)b 0.71 (0.33–1.50)a 2.60 (1.30–5.20) 1.12 (0.65–1.93)b 1.61 (1.05–2.48)a
Mexico (2) 6.49 (4.17–10.09)d 1.08 (0.90–1.30)d 1.75 (1.24–2.48)d 1.29 (0.80–2.11)d 1.00 (0.84–1.20)d 1.06 (0.75–1.48)d
England 13.81 (6.44–28.32) 1.59 (0.34–3.75) 4.53 (2.34–8.58) 2.20 (0.50–5.02) 2.77 (1.36–5.32) 2.60 (1.43–4.81)
Poolede 6.03 (3.61–10.07) 1.13 (0.71–1.79) 2.35 (1.45–3.80) 1.83 (1.35–2.50) 1.61 (1.04–2.47) 1.77 (1.29–2.43)
a Estimated from combining published 1–7 and 8–21 day period risks.
b Estimated from combining published 8–14 and 15–21 day period risks.
c Actually zero events in this period, RI of 0.1 with wide 95% CI used.
d Estimates are for 0–6, 7–30 and 0–30 days with 7–30 estimated by subtraction of 0–6 from 0 to 30 estimates.
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1Pooled using random effects method of DerSimonian and Laird (Metan command
eeded surgical intervention, which was similar to the manage-
ent of cases outside the vaccine risk periods (Table 3). In the
eriod the vaccine was given and in the 5 years prior to the vaccine’s
ntroduction there were no intussusception admissions in which an
nfant died.
The interval from onset of symptoms to admission ranged from
 to 4 days. Five of the 15 (33.3%) infants with onset in the 1–7
ay risk window after the ﬁrst dose were admitted on the same
ay as their symptoms started compared to 29 of the 56 (51.8%)
f those outside the vaccine risk periods, although this difference
as not statistically signiﬁcant (Table 3), and not different when
djusting for age. The duration of the admission ranged from 0 to
2 days and was similar in infants with onset shortly after the ﬁrstta) due to heterogeneity between countries for some periods.
dose and those outside the vaccine risk periods (Table 3), and non-
signiﬁcantly lower when adjusting for age.
Although rotavirus vaccine is contraindicated for children with
a previous intussusception, 3 infants had an admission for intussus-
ception in the 2 months before receiving their ﬁrst dose of rotavirus
vaccine and 10 children went on to have their second dose after con-
ﬁrmed intussusception following the ﬁrst dose. No repeat episodes
of intussusception were recorded in the HES data.
The pooled results for the meta-analysis showed a signiﬁcantly
increased RI after dose one and dose two 21 days after vaccination
(Table 4). A signiﬁcantly increased RI was  also seen following dose
one and two  in the 1–7 day post-vaccination period and also post
dose two in the 8–21 day period.
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. Discussion
This is the ﬁrst study of the risk of intussusception after rotavirus
accine to be reported from the European region and the ﬁrst using
 schedule in which the second dose is given at 3 months of age. Our
elative risk estimate of 13.81 (6.44–28.32) for the 1–7 day period
fter the ﬁrst dose of RV1 is somewhat higher than those obtained
or RVI using the SCCS method in Mexico, Australia and Singapore
Table 4). This may  reﬂect the use of symptom onset in our anal-
sis rather than the later admission date as used by others; had
dmission date been used instead of onset date for the 15 cases in
he 1–7 day period after the ﬁrst dose, 5 would have been assigned
o the 8–21 day risk period, thus decreasing the RI in this earlier
nterval. Our RI estimate for the 1–7 day period after dose two was
ithin the range reported by the other three countries, indicating
hat the earlier age at administration of the second dose in England,
hich is closer to that in countries using the Expanded Programme
n Immunisation schedule recommended by the World Health
rganisation, is unlikely to inﬂuence the vaccine-associated risk of
ntussusception. When pooling results across the six studies there
as an approximate three-fold increased risk 1–21 days after the
rst dose and two-fold increased risk after the second dose. The
haracteristics of the cases in the 1–7 day period after the ﬁrst
ose in our study (where we estimated that 93% were vaccine-
ttributable) were similar to those outside the vaccine risk period,
onﬁrming the ﬁndings from Singapore [10].
We also found a signiﬁcantly elevated risk in the 8–21 day period
fter the second dose but not after the ﬁrst. The results of the other
hree SCCS studies for this post-vaccination period were mixed,
lthough the pooled estimate was consistent with our ﬁndings. The
I for this period will be affected by whether symptom onset or
ospital admission date is used in the analysis, as with the 1–7 day
eriod, though in the opposite direction. Using the overall RI for the
–21 period should capture all vaccine-attributable cases and, in
he meta-analysis, signiﬁcantly elevated RI estimates for the 1–21
ay period were found after both the ﬁrst and second doses; in
ur study in England this gave AR estimates of 1.91 and 1.49 per
00,000 doses respectively.
In the UK, the risk of intussusception after rotavirus vaccine
s explicit in written guidance provided to healthcare profession-
ls administering the vaccine and parents are told to be aware of
bdominal pain, vomiting and redcurrant jelly stools and to contact
 doctor immediately to ensure rapid treatment [22]. In April 2015,
wo deaths from intussusception temporally related to rotavirus
accination were reported in France in infants who did not receive
imely medical care [23]. This led the World Health Organisation
lobal Advisory Committee on Vaccine Safety to publish a state-
ent underlining the importance of close monitoring of infants
fter vaccination and the need for prompt medical care for infants
ith suspected intussusception at any time [24]. In our study, the
nterval between symptom onset and admission was  short (mean
1 day) and similar in cases with a close temporal association with
accination and those outside the post-vaccination risk period.
owever, the causal association with vaccination may  not be recog-
ised as there was absence of any mention of the vaccination in the
edical records in all but one case. This case was one of 10 infants
ho received a second dose despite conﬁrmed intussusception
pisode after their ﬁrst dose. Although none of these infants had
 repeat episode following their second dose, greater awareness of
he contraindications to vaccination and of the vaccine-associated
isk is needed.
This study uses routinely collected hospital data which has
he potential for inaccuracy in the diagnostic coding. While we
inimised misdiagnoses by excluding cases with insufﬁcient
nformation to conﬁrm the diagnosis according to the Brighton
ollaboration criteria, this may  have resulted in exclusion of true
[ (2016) 3684–3689
cases. Furthermore, a recent study found that only 86% of intussus-
ception cases reported to the British Paediatric Surveillance Unit
had a HES admission with an intussusception code [25]. Both of
these factors would lead to an underestimate of the attributable
risk though not the RI estimates, assuming that missed cases were
randomly distributed in relation to the timing of vaccination.
The 2–3 fold elevated risk of intussusception after a ﬁrst and
second dose of RV1 demonstrated by our study, would result
in an estimated 21 additional intussusception cases each year
in England. This number needs to be compared with the 25,000
annual admissions for an acute gastrointestinal infection that the
rotavirus vaccine programme has prevented [14]. The beneﬁt/risk
proﬁle of the programme is therefore still strongly positive [26]. It
is however unclear whether the increased risk of intussusception
in the post-vaccination period translates into a sustained increase
in the absolute risk of an intussusception episode in the ﬁrst year of
life or whether, as suggested by ecological studies, this overall risk
remains unchanged [27]. If so this would suggest that the vaccine
acts as a trigger for an event that would anyway occur albeit
later. Surveillance of intussusception in infants eligible to receive
rotavirus vaccine in England will be continued in order to evaluate
the overall ecological impact of the vaccination programme on this
rare event.
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